Actrapid HM Penfill 100 IU Injection 3 ml Cartridge

Actrapid HM penfill 100 IU Injection 3MI is a prescription based medication that is used to treat Type 1 and Type 2 diabetes mellitus. This is a short acting human insulin that is used in diabetes management. Its generic name is Human insulin which should be taken in 100ml of concentration. It contains insulin with the active ingredient, that helps lower blood glucose level by allowing the body's cells to absorb glucose for energy. Doctors provide this medication for both adults and children based on individual needs and blood sugar control. Don't self administer the injection without consulting the doctor.

Controls blood sugar

Actrapid HM penfill show various side effects like other medication have, patient feel mild as well as severe side effects. Consult the doctor about its symptoms :
● Hypoglycemia (low blood glucose level)
● Anxiety
● Headache
● Nervousness
● Shakiness
● Weight gain
● Pain and swelling
● Redness
● Fast heart rate
● High blood pressure

Doctors recommend injecting the injection before 15-20 minutes before the meal to control the post meal blood sugar. It should be injected into the abdomen, thigh and upper arms of the patient. Do not stop taking it unless the doctor tells you to do it. Actrapid HM penfill 100 IU is the part of the treatment plan that should also include a healthy diet, regular exercise and weight reduction as advised by the doctor.

Insulin which is present in Actrapid HM penfill 100 IU Injection, helps to move glucose into the blood cells. These cells use glucose for energy which keeps the blood sugar level under control. It works similar to the insulin produced, it facilitates reuptake of sugar in muscle and also suppresses the production of sugar in the liver.

• Erdnüß, F., Mohr, A., & Krämer, I. (2022). Longterm physicochemical stability of ready-to-administer human insulin injection solutions 1 IU/mL in 50 mL plastic syringes. Pharmaceutical Technology in Hospital Pharmacy, 7(1), 20210014.
• Katahira, M., Hara, I., & Nishizaki, T. (2005). Insulin allergy decreased by Humulin S (Humulin R) and not by insulin aspart or Actrapid Penfill (Penfill R). Diabetic medicine, 22(10), 1455-1457.
• Schulze, J., & Rietzsch, H. (2014). 7.6 Insulin therapy. A Practical Guide to the Therapy of Type-II-Diabetes: Pathophysiology, Metabolic Syndrome, Differential Therapy, Late Complications, 160.
• Schedule, D., & Agent, A. (2009). Novo Nordisk Canada Inc.
• Santhanam, R., Sharma, S. K., Lomte, N., Baig, L., Kale, S., Chauthankar, S., ... & Jaiswal, A. (2025). Assessing Biosimilarity of Insulin Aspart Injection and NovoRapid® Through Pharmacokinetic and Pharmacodynamic Comparisons in Healthy Volunteers: A Double-Blind, Randomized, Crossover Study. European Journal of Pharmacology, 177881.